Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 11C-PiB Clear all
Completed Phase 1 Interventional

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

NCT01723553
View directory record Official record
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 17, 2026, 5:19 PM EDT
Enrolling by invitation Phase 2 Interventional

Tau PET Outcomes With Anti-amyloid Immunotherapies

NCT06723015
View directory record Official record
Conditions
Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

NCT00855868
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 17, 2026, 5:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630
View directory record Official record
Conditions
Dementia
Interventions
11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

NCT06303921
View directory record Official record
Conditions
Tauopathies
Interventions
11C-M503 PET, Brain MRI, Amyloid PET, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

NCT01826110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[11C]PIB
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 17, 2026, 5:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

NCT01607476
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
C11 PiB, F18 Flutametamol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 17, 2026, 5:19 PM EDT
Completed No phase listed Observational

Long-term Effects of COVID-19

NCT05220514
View directory record Official record
Conditions
COVID-19, SAR-CoV-2
Interventions
(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 17, 2026, 5:19 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Imaging in Demyelinating Diseases

NCT05805839
View directory record Official record
Conditions
Multiple Sclerosis, Inflammatory Demyelinating Disease
Interventions
C-11 ER176 Radiotracer, C11 Pittsburgh Compound B, PET/CT scan, MRI
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Completed No phase listed Observational

11C-PIB PET Study in MESA at Columbia University

NCT03981380
View directory record Official record
Conditions
Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Interventions
11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 17, 2026, 5:19 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
11C-PiB
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 17, 2026, 5:19 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

NFL LONG Prospective Study

NCT04263337
View directory record Official record
Conditions
Concussion, Brain
Interventions
[11C] PiB, [18F] PBR111, [18F] Flortaucipir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
3
States / cities
Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting No phase listed Observational

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

NCT04579120
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

NCT03089827
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

NCT06439992
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
View directory record Official record
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 17, 2026, 5:19 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly

NCT00811122
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PIB PET Scan, FDG-PET Scan
Radiation
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 17, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

PiB PET Scanning in Speech and Language Based Dementias

NCT01623284
View directory record Official record
Conditions
PPA, Primary Progressive Aphasia, Aphasia, Non-fluent Aphasia, Semantic Dementia, Apraxia of Speech, Primary Progressive Nonfluent Aphasia, Progressive Aphasia
Interventions
C-11 PiB, F-18 FDG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 17, 2026, 5:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

University of Pittsburgh Brain Health Initiative

NCT04708613
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451
Diagnostic Test · Drug
Lead sponsor
David Okonkwo, MD, PhD
Other
Eligibility
29 Years to 59 Years · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 5:19 PM EDT